IN THE UNITED STATES PATENT AND TRAINED

10/522119

DTOT Rec'd PCT/ 2 5 JAN

Application No.:

Based on PCT/JP03/09386

Filed:

Intl. Filing 24 JULY 2003

1st Inventor:

Yoshihisa Inoue

For:

Furoisoquinoline Derivative and Use Thereof

Atty. Dkt. No.

3073 US0P

Art Unit:

tba

Examiner:

tba

Allowed:

Batch:

Paper No.:

Information Disclosure Statement

MAIL STOP PCT P.O. Box 1450 Commissioner for Patents Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants request consideration of the references listed on the attached Form PTO/SB/08A and 08B. A legible copy of each listed reference is herewith being provided to the Examiner.

This Information Disclosure Statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached form PTO/SB/08A be returned in accordance with MPEP §609.

Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney.

Respectfully submitt

Dated:

(847) 38**3**-3372 (847) 383-3391

Mark Chao, Ph.D., Reg. No. 37,293

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Attorney for Applicants

Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road Lincolnshire, IL 60069 USA

3073 US0P

PTO/SB/08A (08-03) Approx or use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademax Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control num Complete if Knywn / 5 Substitute for form 1449/PTO Application Number Based on PCt/JP03/09386 Filing Date Intl. Filing 24 JULY 2003 INFORMATION DISCLOSURE First Named Inventor Yoshihisa Inoue STATEMENT BY APPLICANT Art Unit tba (Use as many sheets as necessary) **Examiner Name** tba

Sheet 1

Attorney Docket Number

<u> </u>	1 01			DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	^{US-} 4,012,495	03/15/1977	R. Schmiechen, et al.	
		US-			
		US-	·		
		US-		<u> </u>	
		US-			
-		US-			
		US-			

			IGN PATENT DOCU			
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
1111000	110.	Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant or cited bocument	Or Relevant Figures Appear	T
	A2	WO 01/70746 A1 - Abstract	09/27/2001	Takeda Chemical Industries		
	A3	WO 02/04455 A2	01/17/2002	DuPont Pharmaceuticals		
						L
				<u> </u>		L
						L
	1				1	1

Examiner	Date
Signature	Considered
	1

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

DT01 Pec'd PCT/FT. 2 5 JAN 2003

PTO/SB/08B (08-03)
Appro or use through 07/31/2006. OMB 0651-0031

8

Un	der the Paperwork Red	uction A	t of 1995, no persons ar		and Trademark Unice; U.S. DEPARTMENT OF COMMERCE of information unless it contains a valid OMB control number.		
Substitute for form 1449/PTO				Complete if Known			
				Application Number	Based on PCT/JP03/09386		
INFORMATION DISCLOSURE				Filing Date	Intl. Filing 24 JULY 2003		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Yoshihisa Inoue		
	(Use as many she	ete ae n	ecessary)	Art Unit	tba		
(650 25 // 6/1000 25 // 6/1000 25 //				Examiner Name	tba		
Sheet	2	of	2	Attorney Docket Number	3073 US0P		

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*				
	A4	E. PINTO, et al., "An Improved synthesis of 1(2H)-isoquinolinones: Synthesis and Biological Activity of Novel 2H-pyrando[2,3-h]isoquinolin-1,10-diones and 1(2H)-furol[2,3-h]isoquinolines", Indian Journal of Chemistry, (1992), pp. 578-582, Vol. 31B		
	A5	E. PINTO, et al., "Synthesis and Biological Activity of Novel 1 (2H)-furo[2,3-h]isoquinolinone, (2H)-pyrano[2,3-h]isoquinoline-1,8-dione", Indian Journal of Chemistry, (1994), pp. 552-555, Vol. 33B		
	A6	S.B. CHRISTENSEN, et al., "1,4-Cyclohexanecarboxylates: Potent and Selective Inhibitors of Phosophodiesterase 4 for the Treatment of Asthma", J. Med. Chem., (1998), pp. 821-835, Vol. 41		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.